HIGHLIGHTS
- Who: Shulin Wei 1 et al. from the Department of Endocrinology, Institute of Endocrine and Metabolic Disease, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China have published the paper: Tirzepatide in Treating Metabolic Disorders, in the Journal: (JOURNAL)
- How: This review presents a summary of recent preclinical studies and clinical trials on the application of tirzepatide to treat diabetes obesity MASH cardiovascular disease and kidney disease and reveals the promising prospect of using tirzepatide as a magic bullet in treating metabolic disorders. The trial was conducted in two . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.